Abstract
Bone is comprised of separate inner endosteal and outer periosteal compartments, each with distinct contributions to bone physiology and each maintaining separate pools of cells due to physical separation by the bone cortex. While the skeletal stem cell giving rise to endosteal osteoblasts has been extensively studied, the identification of a periosteal stem cell has been elusive1–5. Here, we identify a periosteal stem cell (PSC) present in the long bones and calvarium of mice that displays clonal multipotency, self-renewal and sits at the apex of a differentiation hierarchy. Single cell and bulk transcriptional profiling show that PSCs display distinct transcriptional signatures in comparison with both other skeletal stem cells and mature mesenchymal cells. While other skeletal stem cells form bone via an initial cartilage template using the endochondral pathway4, PSCs form bone via a direct intramembranous route, providing a cellular basis for the divergence between intramembranous versus endochondral developmental pathways. However there is plasticity in this division, as PSCs acquire endochondral bone formation capacity in response to injury. Genetic blockade of the ability of PSCs to give rise to bone-forming osteoblasts results in selective impairments in cortical bone architecture and defects in fracture healing. A cell analogous to PSCs is present in the human periosteum, raising the possibility that PSCs are attractive targets for drug and cellular therapy for skeletal disorders. Moreover, the identification of PSCs provides evidence that bone contains multiple pools of stem cells, each with distinct physiologic functions.
Keywords: Stem cell, Bone, Periosteum, Osteoblasts
A major limitation to identifying periosteal stem cells has been the lack of genetic markers that discriminate periosteal versus endosteal mesenchyme. While studying the specificity of skeletal targeting cre strains, we observed that Cathepsin K-cre (Ctsk-cre) labels the periosteal mesenchyme. In Ctsk-cre; mTmG reporter mice6, where Ctsk-cre positive cells and their progeny (hereafter CTSK-mGFP cells) are mGFP+, labeling of the periosteal mesenchyme was observed as early as embryonic day 14.5 (Extended data 1a–e). At postnatal day 10, CTSK-mGFP cells were observed in the periosteal mesenchyme and the endosteal marrow compartment, though nearly all the endosteal cells were morphologically consistent with osteoclasts (Fig. 1a, Extended data 1f). Negligible number of osteocytes were CTSK-mGFP+ (Extended data 1g). Flow cytometry of endosteal cells and co-staining for TRAP confirmed that endosteal CTSK-mGFP cells were osteoclasts (Fig. 1b, c panel i-ii). Conversely, the majority of CTSK-mGFP cells in the periosteum were CD45−, TER119−, CD31− (hereafter Lin−) mesenchymal cells (Fig. 1c, panel iii). Periosteal CTSK-mGFP cells include periosteal osteoblasts as shown by expression of type I collagen, RUNX2, alkaline phosphatase (ALPL) and osteocalcin (Fig. 1d, Extended data 1j). Thus, within the mesenchymal compartment, Ctsk-cre selectively labels the periosteum7 (Fig. 1c, panel iv-v).
This labeling suggested that a periosteal stem cell exists within the mesenchymal CTSK-mGFP+ population (Fig. 1a–c). To test this, CTSK-mGFP mesenchymal cells were fractionated by multi-color flow cytometry (Fig. 1 f–g, i–k; Extended data 1i). Three populations were observed within the CTSK-mGFP+ cells lacking THY and 6C38, all of which were CD49fdim, CD51dim: periosteal mesenchymal stem cells (PSCs) (CD200+, CD105−), periosteal progenitor 1 (PP1) (CD200−, CD105−), and periosteal progenitor 2 (PP2) (CD105+, CD200variable) (Fig. 1g panel ii, 1h, Extended data 2a–c). Immunostaining confirmed the presence of CD200+ CTSK-mGFP cells in the periosteum and also identified subsets of CTSK-mGFP cells expressing Gremlin15 and Nestin1 (Fig. 1e, Extended data 1b, 1e, 1k). Consistent with the restriction of hematopoiesis to the endosteal compartment, CTSK-mGFP+ status is mutually exclusive with expression of LEPR, CD146, and CD140α, markers present in mesenchymal cells with the ability to support hematopoiesis2,3,9,10 (Fig. 1i–m, Extended data 2e–g). During embryonic development, periosteal CTSK-mGFP+, CD200+ cells consistent with PSCs was first observed at E14.5 concurrent with the onset of skeletal mineralization and were distinct from CD200+ cells present within the chondroepiphysis (Extended data 1a–e).
PSCs display the stem cell properties of clonal multipotency, self-renewal and the ability to give rise to the entire range of CTSK-mGFP+ cells. Serial mesensphere formation is an in vitro proxy for self-renewal1, and only PSCs possessed the capacity to form tertiary mesenspheres, retaining CD200 through this process (Fig. 2a–c). To determine which periosteal population sits at the apex of the CTSK-mGFP differentiation hierarchy, FACS isolated populations were cultured for 15 days, and subsequently reanalyzed by flow cytometry, where PSCs differentiated into PP1 and PP2 cells in addition to THY+ and 6C3+ cells (Fig. 2d). In contrast, PP1s or PP2s did not produce PSCs in culture (Extended data 2i). Additionally, PSCs demonstrated in vitro clonal multipotency for differentiation into mature osteoblasts and adipocytes (Fig. 2e). Similarly, a clonogenic periosteal population can be identified by pulse labeling in vivo (Extended data 2h). PSCs also possessed chondrocyte differentiation capacity. Together, PSCs are the most stem-like of the CTSK-mGFP populations in vitro.
In contrast to other skeletal MSCs that mediate endochondral ossification, PSCs form bone in vivo via an intramembranous pathway. PSCs and non-CTSK MSCs (Lin−, 6C3−, THY−, CD200+, CD105−, GFP−) were transplanted under the kidney capsule of WT secondary recipients (Fig. 2f, panel i-ii). Both non-CTSK MSCs and PSCs mediated de novo generation of bone organoids (Fig. 2f, panel iv). Consistent with the physiologic restriction of marrow recruitment to the endosteal compartment, non-CTSK MSCs underwent endochondral ossification with cartilage differentiation and recruitment of hematopoietic elements whereas PSCs mediated intramembranous bone formation without hematopoietic recruitment or cartilage formation11 (Fig. 2f, panels iii, v, Extended data 2j–l). Otherwise, non-CTSK MSCs displayed similar performance to PSCs in bone organoid, clonal multipotency and mesensphere assays (Extended data 3a–h). No interconversion between non-CTSK MSCs and PSCs could be observed post-transplant (Extended data 3i–k). Thus, bone contains discrete stem cell populations with differing functional specializations1,2,4,5,12, including a PSC population specialized for periosteal physiology.
Additionally, PSCs sit at the apex of a differentiation hierarchy in vivo and are capable of self-renewal during serial transplantation assays1,9 CTSK-mGFP PSCs were transplanted into the mammary fat pad of female mTmG mice and analyzed over two successive rounds of transplantation (Fig. 2g). After the first round of transplantation, PSCs both self-renewed and gave rise to the entire spectrum of CTSK-mGFP cells observed in native periosteum (Fig. 2h, panels i-iv). Similar results were observed in a kidney capsule system (Extended data. 4a). PSCs from secondary hosts were re-isolated and transplanted into tertiary hosts where they again displayed intact self-renewal and differentiation capacity (Fig. 2h, panels v-viii). In contrast, CTSK-mGFP+ PP1 or PP2 cells did not revert to PSCs after transplantation and were unable to maintain THY−, 6C3− progenitor cells (Extended data 3l–n, 4b–c). Thus, PSCs retain both self-renewal and differentiation capacity through successive rounds of transplantation, indicating they sit at the apex of the CTSK-mGFP differentiation hierarchy.
The specialization of PSCs for intramembranous bone formation was further examined at a well-known site of intramembranous bone formation, the calvarium. Consistent with observations that calvarial sutures contain progenitors that migrate out onto calvarial periosteum as they mature13,14, cells with a PSC immunophenotype exist predominantly in the sutures (Fig. 3a, 3ci, 3d; Extended data 4d–e). In contrast, CTSK-mGFP PP1 and PP2 cells, as well as THY+, CD146+, SCA1+ cells, were predominantly present in the calvarial periosteum outside of the sutures (Fig. 3b–d, Extended data 4f–j). Calvarial PSCs are functionally equivalent to long bone PSCs as seen by sitting at the apex of their differentiation hierarchy during in vitro and in vivo assays, tertiary mesensphere formation capacity, clonal multipotency and bone organoid formation capacity and gene expression (Extended data 5). The few non-CTSK MSC cells in the calvarium displayed low in vitro bone formation capacity (Extended data 5d–f). Thus, PSCs are present in the calvarial sutures, suggesting that PSCs orchestrate intramembranous ossification at multiple anatomic sites.
Transcriptional analysis showed that PSCs from mouse femur were broadly different from both their PP1 and PP2 derivatives and other skeletal MSCs (Fig. 3e, Extended data 6a, 6g). Both PSCs and non-CTSK MSCs shared expression of genes associated with mesenchymal stem/progenitor cells including Runx2 and Sox9, alongside stemness associated genes such as Myc15 and Klf416, whereas PSCs expressed higher levels of Nanog and Wnt5a17 (Fig. 3f). Notably, PSCs displayed increased per cell bone formation capacity than PP1/2 cells after kidney capsule transplantation (Extended data 6b–d). Calvarial PSCs also displayed similar patterns of gene expression as those observed in femoral PSCs (Extended data 5g). In parallel, to empirically determine the populations present within the pool of femoral CTSK-mGFP+, Lin− cells, single cell RNA sequencing was performed using CEL-SEQ218. Mesenchymal CTSK-mGFP+ cells clustered into 4 groups: a group expressing progenitor/stem cell markers19 such as Sox9 and Col2a1, a group expressing osteoblast markers such as Bglap and Alpl, a group expressing Ly6a (Sca1) and a small group with high expression of Acta2 (Fig. 3g–h, Extended data 6e–f). Unsupervised construction of an inferred differentiation trajectory using Monocle20 empirically identified a population corresponding to flow cytometry defined PSCs (Fig. 3i, panel iii-v). Transcriptional markers of mesenchymal stem / progenitor cells were expressed in the early region of this differentiation trajectory containing PSCs (Fig. 3j–k). Thus, combined index sorting/single cell sequencing independently identifies a discrete PSC population similar to that identified by FACS, and PSCs display transcriptional signatures of mesenchymal stem cells and are distinct from other CTSK-mGFP+ populations.
To evaluate the physiologic importance of PSC-derived osteoblasts to bone formation, the ability of PSCs to give rise to osteoblasts was blocked by conditionally deleting Osterix (Osx), a transcription factor essential for osteoblast differentiation21,22, using Ctsk-cre. Osxfl/fl; Ctsk-cre+ mice displayed hypomineralization of the calvarium, uneven periosteal surfaces, and extensive linear intra-cortical pores that gave a characteristic appearance of a double cortex (Fig. 4a–d, Extended data 7a). Endosteal trabecular bone mass was not significantly altered (Extended data 7d). Otherwise, bone morphology and growth plate architecture were intact in Osxfl/fl; Ctsk-cre+ mice aside from a slight reduction in long bone length (Extended data 7b–c). Bone formation rates were significantly reduced in the periosteum of Osxfl/fl; Ctsk-cre+ mice, with a compensatory increase in endosteal bone formation (Fig. 4e, Extended data 7e). TRAP staining showed no changes in osteoclast numbers23 (Extended data 7f–g). Consistent with histomorphometry results, the in vivo and in vitro osteogenic potential of both long bone and calvarial PSCs but not endosteal MSCs was reduced in Osxfl/fl; Ctsk-cre+ mice (Extended data 7h–j). Thus, PSC-derived osteoblasts are necessary for periosteal bone formation and the establishment of normal cortical architecture.
Consistent with prior observations that the periosteum is necessary for fracture repair24,25, PSC-derived osteoblasts expand in response to injury and are necessary for fracture healing. PSCs showed a greater expansion than non-CTSK MSCs in femurs 8 days after fracture (Fig. 4f, Extended data 7k–p, 8, 9a–c). PSCs isolated from the fracture site displayed enhanced osteoblast differentiation capacity on a per cell basis in vitro (Fig. 4g). Thus, fracture markedly increases both the numbers and the osteoblast differentiation capacity of PSCs.
It is a longstanding apparent contraction that periosteum undergoes intramembranous bone formation at baseline while also being necessary for endochondral fracture repair. We examined if PSCs could explain this contraction by switching from a baseline intramembranous bone formation capacity to acquire endochondral bone formation capacity after fracture. While no CTSK-mGFP+ labeling of chondrocytes is observed at baseline, CTSK-mGFP+ cells contributed approximately half of the chondrocytes present in the fracture callus, (Extended data 8a insert c, 9d). PSCs isolated from the fracture callus mediated endochondral ossification after transplantation into the kidney capsule (Fig 4f vii, 4h, Extended data 9f–g). Thus, while there is a clear distinction between intramembranous competent PSCs and endochondral competent MSCs at baseline, injury can introduce plasticity or interconversion between these cell types. This offers an explanation for how the periosteum can contribute to the endochondral process of fracture repair despite being specialized for intramembranous formation at baseline.
Next, the functional contribution of PSC-derived osteoblasts to fracture healing was examined in Osxfl/fl; Ctsk-cre+ mice, which displayed markedly impaired fracture healing with increased rates of fracture non-union and a decrease in the total fracture callus bone volume (Fig. 4i–l). Histologic analysis of the fracture callus was consistent with defects in mineralization with decreased bone and increased cartilage in the callus (Extended data 10a–g).
To establish if a population analogous to PSCs exists in humans, human periosteal tissue from femur was sectioned and stained, demonstrating cells expressing Cathepsin K and CD200 (Fig. 4m). Flow cytometry similarly revealed the presence of a population (Lin− CD90− CD200+, CD105-; hereafter h-PSCs) in human periosteum bearing an immunophenotype similar to that of murine PSCs (Fig. 4n, Extended data 10h–j). These human PSCs were multipotent as they underwent osteogenic, adipogenic and chondrogenic differentiation in vitro (Fig. 4o). When transplanted into the kidney capsule of immunocompromised mice, h-PSCs, h-PP1, and h-PP2 cells all mediated intramembranous bone formation (Fig. 4p, Extended data 10l). Thus, human periosteum contains a population analogous to PSCs.
Here we have identified a stem cell that serves as a physiologic precursor of periosteal osteoblasts, playing a critical role in both fracture healing and modeling of the bone cortex. As the bone cortex is essential for the biomechanical resistance of bone to fracture26–29, isolation of PSCs is likely to facilitate both the development of drugs that increase cortical bone thickness and also cellular therapy for skeletal injury30. Moreover, the existence of a discrete periosteal stem cell demonstrates that bone is comprised of multiple distinct pools of stem cell progenitors, which in turn allows for the functional specialization of each of those stem cells and their derivatives. In this regard, PSCs are specialized for intramembranous bone formation at baseline, providing a cellular basis for long-observed differences between intramembranous and endochondral bone formation. Lastly, the interconversion between PSCs and endochondral competent populations suggests that such interconversions may occur more broadly and contribute to the cellular basis of skeletal pathology.
Methods
Animals:
Cathepsin K-cre (Ctsk-cre) mice were a gift from S. Kato (University of Tokyo, Tokyo, Japan)31. Floxed Osterix (Osxfl/fl) mice were a gift from B. de Crombrugghe (Univeristy of Texas M.S. Anderson Cancer Center, Houston, Texas)32. R26R-Confetti (Stock 017492), β actin-cre ERTM (Stock 004682), NOD scid gamma (NSG, Stock 005557) and mTmG mice (Stock 007676)33 were purchased from Jackson Laboratories. All mice were maintained on a C57Bl6/J background throughout the study. All animals were maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the Weill Cornell Medical College subcommittee on animal care (IACUC). No randomization of mice were done during these experiments. Blinding for experiments was done only for micro computed tomography (μCT) analyses. Sample sizes used at minimum 3 animals per experimental procedure.
Cell line:
Validation for single cell sorting was initially done with RAW264.7 cells from ATCC (Cat # ATCC® TIB-71), a commercially available mouse macrophage cell line. These cells were not independently authenticated since they were obtained directly from ATCC and were only used to validate single cell sorting capabilities prior to experimentation. Cells were tested for mycoplasma using the PlasmoTest™ - Mycoplasma Detection Kit from InvivoGen (Cat # rep-pt2) and PCR analysis. All cells were confirmed to be free of mycoplasma.
Tamoxifen injection:
β-actin creERTM activity was induced at post-natal day 3. 100 mg/kg of Tamoxifen (Sigma) was prepared in corn oil and intraperitoneally injected into nursing females for 3 consecutive days. Control groups were conducted simultaneously by injecting the nursing female with corn oil only. The resulting litters were sacrificed 14 days after induction and femurs were fixed for 4 hours with 4% paraformaldehyde and processed for imaging as described below.
Human samples:
This project was approved by the IRB committee of Memorial Sloan Kettering Cancer Center (MSKCC) (IRB No. 97–094). HIPAA authorization was included in the IRB protocol and all ethical guidelines conform to the 2008 Helsinki declaration. Patient consent was obtained and all identifying patient information was scrubbed at the time of sample procurement.
Isolation of mesenchymal cells:
Skeletal tissue from postnatal day 7, 15 or 32 mice was subjected to both mechanical and enzymatic digestion. The harvested tissue was minced using razor blades and digested for up to 1 hour with Collagenase P (1mg/ml; Roche, cat 11213857001) + Dispase II (2mg/ml; Roche, cat 04942078001) digestion buffer at 37°C with agitation. Media containing 2% serum was added to the digest and the tubes were centrifuged to pellet cells. The supernatant was removed, and the pellet was resuspended in DNase I (2 units/ml) solution and briefly incubated for 5 mins at 37°C. Media was added to the tube and the digested tissue was re-suspended thoroughly by pipetting and then filtered thorough 70-micron nylon mesh. Tubes were centrifuged and the resulting cell pellet was subjected to FACS.
Microdissection of mouse periosteum, calvarial suture and calvarial periosteum was performed under a dissecting microscope and the resulting tissue samples were subjected to the same digestion protocol. For human samples, tissue was treated with Pronase (1mg/ml; Roche, cat 10165921001) for 20 minutes at 37°C under agitation and spun down at 1500 rpm for 10 minutes prior to collagenase treatment as above.
Florescence assisted cell sorting (FACS):
Cells were washed twice with ice cold FACS buffer (2% FBS + 1mM EDTA in PBS), incubated with blocking buffer (1:100 dilution; BD bioscience 553142 for mouse and 564765 for human) for 15 mins at 4°C. Primary antibody dilutions were prepared in brilliant stain buffer (BD bioscience 563794). Cells were incubated in the dark for 1 hour on ice with primary antibody solution, washed 2 to 3 times with FACS buffer, and incubated with secondary antibody solution for 20 minutes. Cells were then washed several times and re-suspended in FACS buffer with DAPI (4–6, Diamidino-2-Phenylindole; 1μg/ml; Invitrogen D1306). FACS was performed using a Becton-Dickinson Aria II equipped with 5 lasers (BD bioscience). Beads (eBioscience 01–1111) were used to set initial compensation. Fluorescence minus one (FMO) controls were used for additional compensation and to assess background levels for each stain. Gates were drawn as determined by internal FMO controls to separate positive and negative populations for each cell surface marker. Typically, 1 to 2 million events were recorded for each FACS analysis, and the data was analyzed using FlowJo (version 10.1). Calculations were made in Excel and bar graphs were generated in GraphPad Prism.
To better depict the FACS gating strategy, we have made changes throughout our figures, using color-coded boxes to illustrate parent/daughter gates. Additionally Extended data. 2d has been provided to show the full details of the gating strategies utilized.
FACS antibodies:
Antibodies for FACS of human samples included CD235a (clone HIR2, eBioscience), CD31 (cloneWM-59, eBioscience), CD45 (BD bioscience), CD90 (clone 5E10, BD bioscience), CD140α (clone aR1, BD bioscience), CD105 (clone 266, BD bioscience), CD200 (clone MRC OX-104, BD bioscience), CD146 (clone P1H12, BD bioscience), CD140α (clone αR1, BD bioscience), CD49f (clone GoH3, BD bioscience), CD51 (clone NKI-M9, Biolegend) CD295 (clone 52263, BD Bioscience). Antibodies for FACS of mouse samples include CD45 (clone 30-F11, BD bioscience), CD31 (MEC13.3, BD bioscience), Ter119 (clone Ter119, BD bioscience), CD90.2 (clone 53–2.1, BD bioscience), BP-1 (clone 6C3, eBioscience), CD200 (clone OX-90, BD bioscience), CD105 (clone MJ7/18, Biolegend), CD146 (clone ME-9F1, BD bioscience), CD140α (clone APA5, Biolegend), CD49f (clone GoH3, BD bioscience), CD51 (clone RMV-7, BD bioscience), Ly6A/E (clone D7, BD bioscience), LeptinR (R&D system), CD61 (clone 2C9.G2, BD bioscience), Streptavidin eFluor 710 (eBioscence), Streptavidin BUV737 (BD bioscience).
Cell culture:
Sorted cells were cultured both under hypoxic (2% O2, 10% CO2, 88% N2) and non-hypoxic conditions (20% O2). In vitro differentiation of FACS isolated populations was conducted under hypoxic conditions (Fig. 2d, Extended data 2i, 3h, 5k–m). Clonal multipotency of sorted cell populations was evaluated under non-hypoxic conditions (Fig. 2e, Fig. 4o, and Extended data 3d, 5c). Mesensphere formation capacity was evaluated under non-hypoxic conditions (Fig. 2a, Extended data 3f, 5a).
Mouse primary cells were grown in complete mesencult medium (basal medium; cat no 05501 + stimulatory supplements; cat no 05502, 05500, Stem Cell Technologies). After initial cell plating, cells were left undisturbed and allowed to grow at 37°C under humidified conditions for a week. Half of the media was replaced every 7 days. Cells were passaged once they were 60–70% confluent with stem pro accutase solution (Gibco, cat no A11105–01).
Sorted human cells were cultured under conditions similar to those described above using a commercial media preparation (basal medium; cat no 05401 + stimulatory supplements; cat no 05402, Stem Cell Technologies).
Mesensphere assays:
For mesensphere assays, FACS isolated single cells were plated at a density of 100 cells / cm2 and allowed to grow in ultra-low adherence culture dishes (Stem Cell Technologies, cat no 27145). Plates were incubated at 37°C supplied with 5% CO2 and left undisturbed for a week. Half of the media was replaced every 7 days. Mesenspheres were dissociated into single cells using Accutase solution (Gibco, cat no A11105–01) and were subsequently re-plated to generate secondary and tertiary mesenspheres.
Clonal differentiation assay:
The differentiation potential of 10 colonies derived from single FACS isolated PSCs was examined (Fig. 2e). Briefly, single FACS sorted cells were plated at a density of 100 cells per 10 cm dish and allowed to form individual colonies. Initial dispersion of the plated cells as single cells was confirmed by light microscopy. Each of the selected colonies were extracted using a cloning cylinder. The extracted cells were regrown for 3–4 days in 12 well plates and then allowed to differentiate under both osteogenic and adipogenic conditions as described below. A similar approach was utilized to analyze clonal differentiation of FACS sorted calvarial PSCs (Extended data 5c).
Osteogenic differentiation and Alizarin red staining:
Sorted cells were expanded and then allowed to differentiate using osteogenic differentiation medium (Stem Pro Osteogenesis Differentiation kit, cat no A10072–01) for 19–28 days. Media was changed every 2 days. At the end of this period, cells were washed with cold PBS and fixed with 70% ethanol for 15 mins on ice. Cells were washed with distilled water and stained with Alizarin red solution for 2–3 mins. Cells were then washed thoroughly with water and air dried prior to microscopic visualization.
Adipogenic differentiation and Oil red O staining:
Adipogenic differentiation was similarly conducted with sorted cells as described above. Briefly, cells were allowed to differentiate in adipogenic differentiation media (Stem Pro Adipogenesis Differentiation kit, cat no A10070–01). Fresh media was added every 2–3 days for a total of 14–20 days. Media was removed, and cells were washed with PBS and fixed with 4% Paraformaldehyde (PFA) for 30 mins at room temperature (RT). Cells were rinsed again with PBS and stained for 30 mins with oil red O working solution (3:2 dilution with water). Cells were then observed under a light microscope after 4–5 washes with PBS.
Chondrogenic differentiation and Alcian blue staining:
Micromass cultures were generated by seeding 1 × 105 cells in 5–10 μl of basal media. Cells were allowed to adhere to a glass slide for 2 hours under highly humidified conditions at 37°C. Chondrogenic differentiation media (Stem Pro Chondrogenesis Differentiation kit, cat no A10071–01) was slowly added and cells were incubated at 37°C supplied with 5% CO2. Cultures were re-fed every 2–3 days and allowed to differentiate for a minimum of 14 days.
At the end point of this study, media was removed, cultures were washed with PBS and fixed with 4% PFA for 30 mins. Cultures were stained for 30 mins with 1% Alcian blue solution, washed three times with 0.1N HCl and then with PBS.
Separately, pellet culture was conducted with 250 × 103 cells seeded in 15 ml polypropylene tubes. The pellet was cultured in chondrogenic differentiation medium, which was changed every 2–3 days for a period of 2 weeks. The pellet was harvested, fixed with 4% PFA and embedded in OCT with 15% sucrose solution. 10 μm thick sections were cut and Alcian blue staining was performed as described.
Surgical procedures:
All surgical procedures were performed under isoflurane (1–4%) anesthesia. Surgical sites were sterilized using a betadine/iodide/isopropanol prep after hair removal by a clipper with a #40 blade and a depilatory cream (Nair). After surgery, the visceral lining or muscle was sutured with absorbable Ethicon vicryl sutures (VWR, cat no 95057–014) prior to closing the skin with wound clips that were removed 2 weeks post-operatively. Animals received intraperitoneal Buprenex (0.5 mg/kg) and oral Meloxicam (2.0 mg/kg) as analgesia prior to surgery and for every 24 hours post-surgery for 3 days. All surgical procedures are approved by the institutional animal care and use committee at Weill Cornell Medical College.
Kidney capsule transplantation model:
Briefly, 8–10-week old male mice were anesthesized and shaved on the left flank and abdomen prior to sterilization of the surgical site. The kidney was externalized thorough a 1cm incision and a 2-mm pocket in the renal capsule was made. A 5 μl matrigel plug (Corning, cat no 356231) containing 8,000 to 10,000 cells was implanted underneath the capsule and the hole was sealed using a cauterizer prior to replacing the kidney back into the body cavity. Recipients for these experiments were syngenic with donors. Moreover, to avoid potential immunogenicity of GFP itself, all transplantation studies of mGFP+ cells were conducted in mTmG hosts that have baseline immunologic tolerance to GFP variants. Animals were euthanized by CO2 after 6 weeks. After sacrifice, kidneys were fixed with 4% PFA for 5 hours and bone formation was detected by micro-CT. Samples were subjected to infiltration, embedding and sectioning as described below. Hematoxylin & Eosin (H&E), Von Kossa staining were performed following previously described protocols34. Standard Safranin O stain and Alizarin red staining was performed to detect cartilage and bone components.
Altogether, over 30 individual mouse transplantation procedures have been conducted across 5 separate days of experimentation to study the intramembranous versus endochondral differentiation preferences of PSCs versus non-CTSK-MSCs.
Mammary fat pad transplantation model:
To facilitate distinguishing host cells from mGFP+ transplanted cells, 3–4-week-old female mTmG mice were utilized, where all host cells were mTomato+. These mice were anesthesized and their lower abdomen was shaved prior to sterilization of the surgical site. A 1–1.5 cm longitudinal incision was made along the midline of the body wall below the sternum and just above the pelvic region. A second 0.5 cm cut was made from the bottom of the midline incision towards the hip of the right hind limb. The skin was carefully pulled away from the peritoneum to expose the inguinal mammary gland. A 2-mm pocket was created in the mammary fat pad just below the lymph node and a 5 μl matrigel plug with desired number of cells was implanted into the pocket. The pocket was sealed by clamping the edges of the cut fat pad together with a toothed forcep. Wound clips were used to close the skin incisions. Animals were euthanized by CO2 at 2.5-weeks post-surgery, and the mammary fat pad was extracted, minced with razor blades and digested at 37°C in digestion buffer (Collagenase P (1 mg/ml) + Dispase II (2 mg/ml) in 2% serum medium) for 30–45 mins. Media was added and the tubes were spun for 10 mins at 1,500 rpm. The supernatant was carefully removed and DNase I solution was added for 5 mins without disturbing the pellet. The reaction was terminated by diluting the digestion solution with media. Tubes were again spun for 10 mins and the resulting pellet was prepared for FACS analysis.
Femur fracture model:
In brief, after anesthesia, an incision above the right anterolateral femur was made after sterilization of the surgical site. The femur and patella were then exposed and a 27-gauge syringe needle was inserted parallel with the long axis of the femur through the patellar groove into the marrow cavity. The needle was then removed and a single cut in the mid-diaphysis of the femur was made using a dremel saw with a diamond thin cutting wheel (VWR, cat no100230–724). A blunt 25-gauge needle was then reinserted into the marrow space through the hole made in the femur to stabilize the fracture. This needle was then trimmed so it would not project into stifle joint space. Muscle was then placed over the injury site and stitched with absorbable sutures prior to closing the skin with wound clips. We performed femur fracture in 6 weeks old Ctsk-cre; mTmG mice (Fig. 4f) and 4 weeks old Ctsk-cre; Osx flox mice (Fig. 4i). Mice were euthanized by CO2 after 3 weeks.
Sample preparation for cryo-sectioning:
Freshly extracted mouse samples were fixed with 4% Paraformaldehyde (PFA) for 4 hours at 4°C. Samples were washed with PBS and decalcified with 0.5M EDTA for 1–5 days depending on the age of the sample. Samples were incubated with infiltration solution (20% sucrose + 2% PVP in PBS) in rocking conditions until they sank to the bottom of the tube. Embedding was performed with OCT + 15% sucrose and samples were preserved at −80°C. 10–20 μm thick sections were cut using a Leica cryostat.
Immunohistochemistry (IHC):
Frozen samples were thawed at room temperature (RT) and rehydrated with PBS, permeabilized with PBS + 0.3% Triton X-100 for 15mins, and blocked for 1hour with 5% donkey serum in PBS (blocking buffer). Dilutions of primary antibodies were freshly prepared in blocking buffer. Samples were incubated overnight with primary antibodies at 4°C, then washed three times with PBS. Secondary antibodies (1:2000 dilution) were added to the sample for 1–2 hours, followed by washing three times with PBS. DAPI (300 nM) was added for 5–10 mins and the samples were mounted with antifade mounting solution (Life technologies, cat no P36970). Imaging was performed with a Zeiss LSM 880 with Airyscan high resolution detector confocal microscope.
For IHC of mesenspheres, mesenspheres were extracted and allowed to adhere on glass chamber slides for 24 hours. Spheres were fixed with 4% PFA for 15 mins at RT, washed twice with PBS, permeabilized with PBS + 0.5% Triton X-100 for 10 mins and blocked for 1–2 hours with blocking buffer (PBS + 2% BSA + 10% horse serum + 0.5% Triton X-100). Primary antibody dilutions were prepared in blocking buffer, and added to the spheres followed by overnight incubation at 4°C. Samples were washed three times with PBS and incubated with secondary antibody for 1hour and DAPI solution for 10 mins. Samples were subsequently processed for imaging as described above.
Primary antibodies for IHC:
Primary antibodies used were specific for Collagen type I (Abcam, ab34710, 1:100 dilution), Collagen type II (Millipore, MAB8887, 1:100 dilution), murine CD200 (Abcam, ab33734, 1:100 dilution), Nestin (Abcam, ab11306, 1:200 dilution), Gremlin 1 (Abcam, ab189267, 1:50 dilution), COMP (Abcam, ab74524, 1:50 dilution), Aggrecan (Abcam, ab3778, 1:100 dilution), Thy1.2 (Invitrogen, cat no. 14-0902-82, 1:50 dilution, 6C3 (Invitrogen, cat no. 14-5891-82 (1:50 dilution), CD105 (Abcam, ab107595, 1:100 dilution), Runx2 (Abcam, ab76956, 1:200 dilution), Alpl (Abcam, ab108337, 1:100 dilution), Osteocalcin (Abcam, ab93876, 1:100 dilution), CD146 (Abcam, ab75769, 1:100 dilution), CD140α (Abcam, ab96569, 1:100 dilution), CD200 (Abcam, ab203887, 1:200 dilution), Tartrate Resistant Acid Phosphatase (TRAP) (Abcam, ab185716, 1:50 dilution), and Cathepsin K (Abcam, ab19027, 1:200 dilution).
Calcein labelling:
Calcein stock solution (2.5 mg/ml) was freshly prepared in calcein buffer (ddH2O + 2% NaHCO3+ 150 mM NaCl). 4 weeks old Ctsk-cre; Osxflox mice from the same litter were given subcutaneous calcein injection (10 mg/kg) followed by a second injection after 2 days. Mice were euthanized after 24 hours, fixed overnight in 10% formalin solution and then stored in 70% ethanol. Non-decalcified femur sections were prepared for plastic embedding according to a previously published protocol34.
Histomorphometry:
Mice underwent dual calcein labeling, and undecalcified femur sections were prepared for analysis and stained for TRAP as previously described34. Dynamic histomorphometry parameters were measured using the Osteomeasure Analysis system (Osteometrics) and reported following standard nomenclature35. Mineral apposition rate (MAR; μm/day), bone formation rate / bone surface (BFR/ BS; μm3/mm2/day), bone volume (BV; mm3), bone volume / total volume (BV/TV), osteoclast number / bone perimeter (No. Oc / B.Pm) were determined.
Micro-CT and Paraffin embedding:
Micro computed tomography (μCT) was conducted following the previously described parameters36 on a Scanco Medical Micro-CT35 system at the Citigroup Biomedical Imaging Core. μCT operators and evaluators were blinded to the experimental groups under analysis. Human periosteal samples were fixed overnight with 4% PFA at 4°C. Samples were decalcified with 0.5M EDTA for 5–6 days and then subjected to paraffin embedding. The Translational Research Pathology Core at Weill Cornell performed paraffin embedding, sectioning and staining (H&E; CD 200 and Cathepsin K stain for human samples) following a previously published protocol36.
Bulk RNA sequencing:
Bulk RNA sequencing was performed on sorted PSC, PP1, PP2, and non-CTSK MSC cell populations isolated from 6-day old mouse femurs. cDNA libraries were generated using the Illumina TruSeq RNA Sample Preparation kit and sequenced on HiSeq4000 sequencer. Tophat2 was used to align raw sequencing reads to the mm10 mouse reference genome. Differential expression analysis was performed using DESeq2 package. The heatmap plot was generated using heatmap.2 in the R gplots package, where the expression values were normalized per gene over all samples37. For each gene, the mean and standard deviation (stdev) of expression over all samples was calculated, and the expression value underwent linear transformation using the formula (RPKM-mean)/stdev. For 16 bulk RNA samples, the average raw reads per sample was 46.2 million.
Single cell RNA sequencing using CEL-SEQ2:
Validation for single cell sorting was initially done with RAW264.7 cells using 384 well plates. Single cell sorting was confirmed thorough observation of growth of a single colony from the sorted cell (Extended data 6h). We found that cells were sorted into wells at 93% efficiency and the detected doublets were less than 2% (Extended data 6i).
For the experiment, CTSK-mGFP positive cells isolated from 6-day old mouse femur were sorted by FACS (Bencton - Dickinson Influx) and plated into individual wells of a 384 well-plate pre-loaded with unique barcoded RT-primers. After sorting, cells were snap frozen on dry ice before being submitted to the New York Genome Center (NYGC) for cDNA synthesis and library preparation. cDNA synthesis was performed in individual wells using a template-switching mechanism followed by PCR amplification. All barcoded amplified cDNA was then pooled and run on a pico-green assay and Fragment Analyzer to evaluate sample concentration and quality, respectively. Libraries were generated from 300 pg of pooled cDNA using the Nextera XT library preparation kit (Illumina). The library was then sequenced with custom sequencing primers across two lanes of a 25bp × 75bp rapid run (HiSeq 2500 instrument). Read 1 was composed of the cell barcode and unique molecular identifier (UMI), while read 2 was used to map the transcript to the mouse genome. After sequencing, the alignment and analysis was done using the NYGC re-tooled pipeline based on Drop seq Core tools38 (McCarroll lab) which provided basic QC and expression analysis. The delivered data contained FASTQ, Bam files and an expression matrix.
Seurat analysis:
Seurat version 2.0.1 and R version 3.4.1 were used for analysis of single cell RNA sequencing data39. Cells expressing at least 200 but not more than 5,500 genes were retained for analysis. Genes expressed in less than 3 cells were not taken into consideration. A total of 658 single cells were analyzed for the total number of unique molecular identifiers (UMIs) per cell, percent mitochondrial gene expression, percent ribosomal gene expression, and cell cycle. Initial clustering analysis showed an even distribution of mitochondrial gene content across clusters, so this was not considered further (data not shown). Cell cycle analysis was performed using a previously published approach40. Regression was performed to remove effects associated with cell cycle state, the number of UMI and ribosomal gene content. Clustering was performed using the first 12 principal components and clusters were visualized using t-SNE projection.
Monocle analysis:
Cell trajectory analysis was performed by using Monocle on CTSK-mGFP cells. Monocle version 2.4.0 and R version 3.4.0 was used to conduct analysis on the single cell sequencing data. Monocle analysis41–43 was performed using negbinomial. size function and the data was loaded using sparseMatrix. Quality control was performed by filtering low quality cells including dead cells, empty wells in the plate and doublets. The mRNA threshold was defined and cells with mRNA content between 35,000 through 295,000 were analyzed (Extended data 6j). The same CEL-SEQ2 dataset as used above was loaded for analysis (Extended data 6k). Cell trajectory was obtained using genes selected by a PCA-based method for cell ordering according to previously described methods41–43. Regression was performed to remove effects associated with cell cycle state and ribosomal gene content. A list of differentially expressed genes that change as a function of pseudo-time was obtained using fullModelFormulaStr. Genes that were significant at 10% false discovery rate were selected. Heat maps to visualize pseudo-time dependent genes were generated by using a subset of the significant genes.
Statistical analyses:
All data are shown as the mean ± standard deviation (S.D.) or standard error of the mean (S.E.M.) as indicated. Where applicable, we first performed the Shapiro-Wilk normality test for checking normality. For comparisons between two groups, a two-tailed, unpaired Student’s t-test was used. If normality tests failed, Mann-Whitney tests were used. For comparisons of three or more groups, one-way ANOVA was used if normality tests passed, followed by Tukey`s multiple comparison test for all pairs of groups. If normality tests failed, Kruskal-Wallis test was performed and followed by Dunn`s multiple comparison test. GraphPad PRISM software (v6.0a, La Jolla, CA) was used for statistical analysis. P < 0.05 was considered statistically significant.
Data availability
RNA sequencing and Single Cell sequencing data will be available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106237. GSE106235 and GSE106236 are the subseries linked to GSE106237 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106235; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106236). Microscopy images will be available upon reasonable request.
Extended Data
Supplementary Material
Acknowledgements
This project was funded by the Office of the Director of the NIH under award DP5OD021351 given to MBG. MBG holds a Career Award for Medical Scientists from the Burroughs Welcome Foundation and a Basil O’Connor Award from the March of Dimes. This content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. We thank Drs. Douglas Ballon, Bin He, Sushmita Mukherjee and the Flow Cytometry Core, Genomics Resources Core, Optical Microscopy Core and the Citigroup Biomedical Imaging Core at Weill Cornell Medicine for their technical support, Drs. Barry Sleckman and Todd Evans for insightful manuscript comments.
Footnotes
Online Content
The Methods, statement of Data availability and Nature Research reporting summaries along with additional References and Extended data will be available in the online version of the paper.
Conflicts of interest
The authors declare no competing financial interests.
References
- 1.Mendez-Ferrer S et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829–834, doi: 10.1038/nature09262 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhou BO, Yue R, Murphy MM, Peyer JG & Morrison SJ Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15, 154–168, doi: 10.1016/j.stem.2014.06.008 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Morikawa S et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. The Journal of experimental medicine 206, 2483–2496, doi: 10.1084/jem.20091046 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Chan CK et al. Identification and specification of the mouse skeletal stem cell. Cell 160, 285–298, doi: 10.1016/j.cell.2014.12.002 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Worthley DL et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 160, 269–284, doi: 10.1016/j.cell.2014.11.042 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nakamura T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130, 811–823, doi: 10.1016/j.cell.2007.07.025 (2007). [DOI] [PubMed] [Google Scholar]
- 7.Yang W et al. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature 499, 491–495, doi: 10.1038/nature12396 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Chan CK et al. Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. Proc Natl Acad Sci U S A 110, 12643–12648, doi: 10.1073/pnas.1310212110 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Sacchetti B et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324–336, doi: 10.1016/j.cell.2007.08.025 (2007). [DOI] [PubMed] [Google Scholar]
- 10.Pinho S et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. The Journal of experimental medicine 210, 1351–1367, doi: 10.1084/jem.20122252 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chan CK et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature 457, 490–494, doi: 10.1038/nature07547 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Bi Y et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nature medicine 13, 1219–1227, doi: 10.1038/nm1630 (2007). [DOI] [PubMed] [Google Scholar]
- 13.Maruyama T, Jeong J, Sheu TJ & Hsu W Stem cells of the suture mesenchyme in craniofacial bone development, repair and regeneration. Nat Commun 7, 10526, doi: 10.1038/ncomms10526 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Zhao H et al. The suture provides a niche for mesenchymal stem cells of craniofacial bones. Nature cell biology 17, 386–396, doi: 10.1038/ncb3139 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Cartwright P et al. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132, 885–896, doi: 10.1242/dev.01670 (2005). [DOI] [PubMed] [Google Scholar]
- 16.Li Y et al. Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4. Blood 105, 635–637, doi: 10.1182/blood-2004-07-2681 (2005). [DOI] [PubMed] [Google Scholar]
- 17.Yang Y, Topol L, Lee H & Wu J Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 130, 1003–1015 (2003). [DOI] [PubMed] [Google Scholar]
- 18.Hashimshony T et al. CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. Genome biology 17, 77, doi: 10.1186/s13059-016-0938-8 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ono N, Ono W, Nagasawa T & Kronenberg HM A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. Nature cell biology 16, 1157–1167, doi: 10.1038/ncb3067 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Trapnell C et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nature biotechnology 32, 381–386, doi: 10.1038/nbt.2859 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Baek WY, de Crombrugghe B & Kim JE Postnatally induced inactivation of Osterix in osteoblasts results in the reduction of bone formation and maintenance. Bone 46, 920–928, doi: 10.1016/j.bone.2009.12.007 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Nakashima K et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002). [DOI] [PubMed] [Google Scholar]
- 23.Aliprantis AO et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. The Journal of clinical investigation 118, 3775–3789, doi: 10.1172/JCI35711 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Utvag SE, Grundnes O & Reikeraos O Effects of periosteal stripping on healing of segmental fractures in rats. Journal of orthopaedic trauma 10, 279–284 (1996). [DOI] [PubMed] [Google Scholar]
- 25.van Gastel N et al. Engineering vascularized bone: osteogenic and proangiogenic potential of murine periosteal cells. Stem cells 30, 2460–2471, doi: 10.1002/stem.1210 (2012). [DOI] [PubMed] [Google Scholar]
- 26.Allen MR, Hock JM & Burr DB Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35, 1003–1012, doi: 10.1016/j.bone.2004.07.014 (2004). [DOI] [PubMed] [Google Scholar]
- 27.Ozaki A, Tsunoda M, Kinoshita S & Saura R Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process. J Orthop Sci 5, 64–70 (2000). [DOI] [PubMed] [Google Scholar]
- 28.Yukata K et al. Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1–34 treatment. Bone 62, 79–89, doi: 10.1016/j.bone.2014.02.002 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Malizos KN & Papatheodorou LK The healing potential of the periosteum molecular aspects. Injury 36 Suppl 3, S13–19, doi: 10.1016/j.injury.2005.07.030 (2005). [DOI] [PubMed] [Google Scholar]
- 30.Bianco P et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature medicine 19, 35–42, doi: 10.1038/nm.3028 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
Additional References:
- 31.Nakamura T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130, 811–823, doi: 10.1016/j.cell.2007.07.025 (2007). [DOI] [PubMed] [Google Scholar]
- 32.Nakashima K et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002). [DOI] [PubMed] [Google Scholar]
- 33.Muzumdar MD, Tasic B, Miyamichi K, Li L & Luo L A global double-fluorescent Cre reporter mouse. Genesis 45, 593–605, doi: 10.1002/dvg.20335 (2007). [DOI] [PubMed] [Google Scholar]
- 34.Fukuda T et al. Sema3A regulates bone-mass accrual through sensory innervations. Nature 497, 490–493, doi: 10.1038/nature12115 (2013). [DOI] [PubMed] [Google Scholar]
- 35.Dempster DW et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 28, 2–17, doi: 10.1002/jbmr.1805 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Greenblatt MB et al. CHMP5 controls bone turnover rates by dampening NF-kappaB activity in osteoclasts. The Journal of experimental medicine 212, 1283–1301, doi: 10.1084/jem.20150407 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Crespo M et al. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nature medicine 23, 878–884, doi:10.1038/nm.4355 10.1038/nm.4355http://www.nature.com/nm/journal/v23/n7/abs/nm.4355.html#supplementary-informationhttp://www.nature.com/nm/journal/v23/n7/abs/nm.4355.html#supplementary-information (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Macosko EZ et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell 161, 1202–1214, doi: 10.1016/j.cell.2015.05.002 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Satija R, Farrell JA, Gennert D, Schier AF & Regev A Spatial reconstruction of single-cell gene expression data. Nature biotechnology 33, 495–502, doi: 10.1038/nbt.3192 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Tirosh I et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196, doi: 10.1126/science.aad0501 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Trapnell C et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nature biotechnology 32, 381–386, doi: 10.1038/nbt.2859 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Qiu X et al. Single-cell mRNA quantification and differential analysis with Census. Nature methods 14, 309–315, doi: 10.1038/nmeth.4150 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Qiu X et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Meth advance online publication, doi:10.1038/nmeth.4402 10.1038/nmeth.4402http://www.nature.com/nmeth/journal/vaop/ncurrent/abs/nmeth.4402.html#supplementary-informationhttp://www.nature.com/nmeth/journal/vaop/ncurrent/abs/nmeth.4402.html#supplementary-information (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
RNA sequencing and Single Cell sequencing data will be available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106237. GSE106235 and GSE106236 are the subseries linked to GSE106237 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106235; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106236). Microscopy images will be available upon reasonable request.